	US 12,188,938 B2
	Anti-VISTA antibodies and fragments
Linda A. Snyder, Pottstown, PA (US); Gordon Powers, Malvern, PA (US); Manuel Alejandro Sepulveda, Spring House, PA (US); and John D. Alvarez, Spring House, PA (US)
Assigned to JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed on Mar. 18, 2021, as Appl. No. 17/205,193.
Application 17/205,193 is a division of application No. 15/738,013, granted, now 11,009,509, previously published as PCT/IB2016/000886, filed on Jun. 23, 2016.
Claims priority of provisional application 62/187,659, filed on Jul. 1, 2015.
Claims priority of provisional application 62/184,108, filed on Jun. 24, 2015.
Prior Publication US 2021/0318322 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC G01N 33/57492 (2013.01) [C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70532 (2013.01)]

18 Claims

1. A nucleic acid which encodes an antibody that binds to human V-domain Ig Suppressor of T cell Activation (VISTA) protein, wherein the antibody comprises:

a) an antibody VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 31, a VH CDR2 having the amino acid sequence of SEQ ID NO:32 and a VH CDR3 having the amino acid sequence of SEQ ID NO:33;

b) an antibody VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO: 34, a VL CDR2 having the amino acid sequence of SEQ ID NO:35 and a VL CDR3 having the amino acid sequence of SEQ ID NO:36;

c) a murine antibody heavy chain constant region; and

d) a murine antibody light chain constant region.